185 related articles for article (PubMed ID: 38148578)
1. Clinical outcome and molecular landscape of patients with ARID1A-loss gastric cancer.
Sun M; Gu Y; Fang H; Shao F; Lin C; Zhang H; Li H; He H; Li R; Wang J; Liu H; Xu J
Cancer Sci; 2024 Mar; 115(3):905-915. PubMed ID: 38148578
[TBL] [Abstract][Full Text] [Related]
2. Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy.
Gu Y; Zhang P; Wang J; Lin C; Liu H; Li H; He H; Li R; Zhang H; Zhang W
Cancer Immunol Immunother; 2023 May; 72(5):1199-1208. PubMed ID: 36369379
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of ARID1A mutations with mRNA levels and protein expression in gastric carcinoma.
Hwang I; Cho Y; Kang SY; Kim DG; Ahn S; Lee J; Kim KM
Pathol Res Pract; 2024 Mar; 255():155063. PubMed ID: 38324965
[TBL] [Abstract][Full Text] [Related]
4. Loss of ARID1A Expression is Related to Gastric Cancer Progression, Epstein-Barr Virus Infection, and Mismatch Repair Deficiency.
Han N; Kim MA; Lee HS; Kim WH
Appl Immunohistochem Mol Morphol; 2016; 24(5):320-5. PubMed ID: 26067140
[TBL] [Abstract][Full Text] [Related]
5. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer.
Kim YB; Ahn JM; Bae WJ; Sung CO; Lee D
Int J Cancer; 2019 Aug; 145(4):916-926. PubMed ID: 30664822
[TBL] [Abstract][Full Text] [Related]
6. Impact of intratumoural CD96 expression on clinical outcome and therapeutic benefit in gastric cancer.
Xu C; Fang H; Gu Y; Yu K; Wang J; Lin C; Zhang H; Li H; He H; Liu H; Li R
Cancer Sci; 2022 Dec; 113(12):4070-4081. PubMed ID: 35997524
[TBL] [Abstract][Full Text] [Related]
7. Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinoma.
Xu Z; Jiang W; Liu L; Qiu Y; Wang J; Dai S; Guo J; Xu J
Cancer Immunol Immunother; 2024 Apr; 73(5):95. PubMed ID: 38607586
[TBL] [Abstract][Full Text] [Related]
8. The clinicopathological significance of SWI/SNF alterations in gastric cancer is associated with the molecular subtypes.
Huang SC; Ng KF; Chang IY; Chang CJ; Chao YC; Chang SC; Chen MC; Yeh TS; Chen TC
PLoS One; 2021; 16(1):e0245356. PubMed ID: 33481850
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial Analysis of AT-Rich Interaction Domain 1A and CD47 in Gastric Cancer Patients Reveals Markers of Prognosis.
Zhao Q; Cai Q; Yu S; Ji J; Zhu Z; Yan C; Zhang J
Front Cell Dev Biol; 2021; 9():745120. PubMed ID: 34805154
[No Abstract] [Full Text] [Related]
10. Loss of ARID1A expression is associated with systemic inflammation markers and has important prognostic significance in gastric cancer.
Wang X; Che K; Shi T; Liu Q; Xu X; Wu H; Yu L; Liu B; Wei J
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1583-1595. PubMed ID: 35294647
[TBL] [Abstract][Full Text] [Related]
11. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
12. The Role of the AT-Rich Interaction Domain 1A Gene (
Li JJ; Lee CS
Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38275587
[TBL] [Abstract][Full Text] [Related]
13. ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report.
Durán M; Faull I; Lastra E; Laes JF; Rodrigo AB; Sánchez-Escribano R
J Med Case Rep; 2021 Feb; 15(1):89. PubMed ID: 33608032
[TBL] [Abstract][Full Text] [Related]
14. ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes.
Akinjiyan FA; Nassief G; Phillipps J; Adeyelu T; Elliott A; Abdulla F; Zhou AY; Souroullas G; Kim KB; Vanderwalde A; Park SJ; Ansstas G
Sci Rep; 2024 Feb; 14(1):3444. PubMed ID: 38341515
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and immune infiltration significance of ARID1A in TCGA molecular subtypes of gastric adenocarcinoma.
Zhang Z; Li Q; Sun S; Ye J; Li Z; Cui Z; Liu Q; Zhang Y; Xiong S; Zhang S
Cancer Med; 2023 Aug; 12(16):16716-16733. PubMed ID: 37366273
[TBL] [Abstract][Full Text] [Related]
16. ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis.
Barisic D; Chin CR; Meydan C; Teater M; Tsialta I; Mlynarczyk C; Chadburn A; Wang X; Sarkozy M; Xia M; Carson SE; Raggiri S; Debek S; Pelzer B; Durmaz C; Deng Q; Lakra P; Rivas M; Steidl C; Scott DW; Weng AP; Mason CE; Green MR; Melnick A
Cancer Cell; 2024 Apr; 42(4):583-604.e11. PubMed ID: 38458187
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Significance of ARID1A Expression Patterns Varies with Molecular Subtype in Advanced Gastric Cancer.
Kim JY; Park CK; Noh S; Cheong JH; Noh SH; Kim H
Gut Liver; 2023 Sep; 17(5):753-765. PubMed ID: 36789575
[TBL] [Abstract][Full Text] [Related]
18. Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1.
Zhang Q; Yan HB; Wang J; Cui SJ; Wang XQ; Jiang YH; Feng L; Yang PY; Liu F
Oncotarget; 2016 Jul; 7(29):46127-46141. PubMed ID: 27323812
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral heterogeneity and loss of ARID1A expression in gastric cancer correlates with increased PD-L1 expression in Western patients.
Tober JM; Halske C; Behrens HM; Krüger S; Röcken C
Hum Pathol; 2019 Dec; 94():98-109. PubMed ID: 31704366
[TBL] [Abstract][Full Text] [Related]
20. The effects of ARID1A mutations on colorectal cancer and associations with PD-L1 expression by stromal cells.
Kamori T; Oki E; Shimada Y; Hu Q; Hisamatsu Y; Ando K; Shimokawa M; Wakai T; Oda Y; Mori M
Cancer Rep (Hoboken); 2022 Jan; 5(1):e1420. PubMed ID: 34042312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]